# Norm

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/norm

- Industry: Medical Devices & Equipment
- Headquarters: Dublin, Ireland
- Website: www.fire1foundry.com
- Total disclosed funding: $57M
- Latest round: Series B (Jan 26, 2018)
- Investors on record: 7

## About

Based in Ireland, Norm specializes in innovative heart monitoring solutions designed to empower heart failure patients to manage their health from home through a revolutionary implant and monitoring system.Norm is a medical device company established in Dublin, Ireland, in 2014, focusing on heart failure management. Founded by Hanson Gifford, the company has engaged in six deals to date, with its most recent investment round occurring on January 7, 2025. The latest round raised USD 120.00 mn, co-led by Polaris Partners and Elevage Medical Technologies, with participation from various other investors, including Medtronic and New Enterprise Associates. The company has seen no significant pivots in its operation since inception, nor is it known to have subsidiaries.Norm offers a groundbreaking medical device that empowers patients with heart failure to monitor their heart health from home. The core product is a heart monitoring system featuring a same-day implant, a wearable belt for daily use, and a mobile application for real-time heart metric tracking. This solution is designed to support patients' independence in health management while ensuring healthcare providers receive alerts for any irregular readings. Norm primarily targets markets in North America and Europe, focusing on heart failure patients, their families, and healthcare professionals involved in their care.Norm's revenue model is centered on direct-to-consumer sales and partnerships with healthcare providers. The company charges for the initial implant procedure and provides ongoing access to the mobile monitoring service through subscription plans. This approach allows for continuous engagement and ensures that both patients and clinicians remain informed about the patient's heart health. The flagship product and its services aim to enhance patient engagement, leading to improved health outcomes and satisfaction.In January 2025, Norm raised USD 120.00 mn in venture funding to support the completion of its pivotal clinical trial of the Norm system. The company plans to expand its market presence by introducing new products designed for heart health management, targeting both North American and European markets. The recent funding will facilitate the development and launch of these innovations, further solidifying Norm's commitment to enhancing patient care in heart failure management.

## Funding rounds

- Series B, Jan 26, 2018, $47M — New Enterprise Associates, Seventure Partners, Gilde Healthcare, Gimv, Medtronic, Covidien, Lightstone Ventures
- Series A, Dec 22, 2016, $6.5M — New Enterprise Associates, Medtronic, Covidien, Lightstone Ventures
- Series A, Dec 23, 2013, $3.6M — New Enterprise Associates, Covidien, Lightstone Ventures

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B
- Covidien — Series A, Series B
- Lightstone Ventures (https://capitalatlas.ai/funds/lightstone-ventures) — Series A, Series B
- Medtronic — Series A, Series B
- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series B
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series B
- Gimv (https://capitalatlas.ai/funds/gimv) — Series B